Cargando…
Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents
Autores principales: | Wang, Liang-Chuan S, Koblish, Holly, Hansbury, Michael, Zhang, Yue, Yang, Gengjie, Burn, Timothy, Waeltz, Paul, Rupar, Mark, Yue, Eddy, Douty, Brent, Maduskuie, Thomas, Falahatpisheh, Nikoo, Li, Yun-Long, Combs, Andrew P, Hollis, Gregory, Huber, Reid, Scherle, Peggy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649283/ http://dx.doi.org/10.1186/2051-1426-3-S2-P377 |
Ejemplares similares
-
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase
1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017) -
INCB054828 (pemigatinib), a potent and selective inhibitor of
fibroblast growth factor receptors 1, 2, and 3, displays activity against
genetically defined tumor models
por: Liu, Phillip C. C., et al.
Publicado: (2020) -
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2014) -
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022) -
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
por: Rios-Doria, Jonathan, et al.
Publicado: (2020)